IBT_B: Operating loss widened in Q1 2026 as IBP-9414 nears FDA submission and commercialization

About this update from Infant Bacterial Therapeutics Ab Class B

Q1 2026 saw increased operating losses due to higher development and regulatory costs, but cash flow improved year-over-year. Regulatory progress for IBP-9414 continues, with FDA submission planned for 2026 and commercialization preparations underway.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Infant Bacterial Therapeutics Ab Class B